New Drug, Actilon, In Development | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Another Treatment Development Alliance

Back to News Homepage
Next

Zandaxin Announcement December 2005

New Drug, Actilon, In Development

The Editors at Hepatitis Central
September 28, 2005

Print this page

Another new approach in the pipeline. As we’ve always said, with millions of people infected, the drug and biotech companies are falling over each other to come up with viable treatments to improve on what is currently available.

NEW YORK, Sept 27 (Reuters) – Coley Pharmaceutical Group Inc. (COLY.O: Quote, Profile, Research) on Tuesday said it is starting an early-stage clinical trial of an experimental drug to treat chronic Hepatitis C virus.

Coley expects preliminary data from the Phase Ib study of the drug, Actilon, to be available in the second half of 2006.

The study will involve 60 patients infected with the virus, who will be divided into different treatment groups over a period of three months. Some patients will take only Actilon, some will take it in combination with one or two standard treatments, and some will take standard treatments without Actilon.

The company, which went public last month, has also attracted attention because of three other promising experimental drugs, especially ProMune, which is entering late-stage trials against non-small cell lung cancer. Coley, based in Wellesley, Massachusetts, is developing that product with Pfizer Inc. (PFE.N: Quote, Profile, Research).

Its drugs are designed to stimulate the immune system by acting on proteins called Toll-like receptors. Actilon acts through the Toll-like receptor 9 found in dendritic cells and B cells, which are mainstays of the immune system.

Shares of Coley were up $1.52, or 9.4 percent, to $17.64 on Nasdaq. (Additional reporting by Ransdell Pierson)

No Comments - be the first!
Share
Share
Previous

Another Treatment Development Alliance

Back to News Homepage
Next

Zandaxin Announcement December 2005

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.